MUC1 and neoplasm: A Phase I clinical study revealed that gatipotuzumab was safe, well tolerated, and had clinical benefits in MUC1-positive patients with advanced solid tumors, while a Phase II clinical study showed that gatipotuzumab treatment had no obvious benefits over a placebo in tumor patients [22,23].